nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Methotrexate—muscle cancer	0.566	0.765	CbGbCtD
Alprostadil—ABCC4—Methotrexate—muscle cancer	0.174	0.235	CbGbCtD
Alprostadil—PTGER1—renal system—muscle cancer	0.0069	0.0613	CbGeAlD
Alprostadil—PTGER2—tendon—muscle cancer	0.00568	0.0505	CbGeAlD
Alprostadil—PTGER2—bone marrow—muscle cancer	0.0055	0.0489	CbGeAlD
Alprostadil—PTGER2—vagina—muscle cancer	0.00527	0.0468	CbGeAlD
Alprostadil—PTGER2—testis—muscle cancer	0.00471	0.0418	CbGeAlD
Alprostadil—PTGER1—head—muscle cancer	0.00462	0.041	CbGeAlD
Alprostadil—PTGIR—smooth muscle tissue—muscle cancer	0.00443	0.0393	CbGeAlD
Alprostadil—PTGIR—renal system—muscle cancer	0.00426	0.0379	CbGeAlD
Alprostadil—Balanitis—Doxorubicin—muscle cancer	0.00395	0.0272	CcSEcCtD
Alprostadil—SLCO3A1—renal system—muscle cancer	0.00376	0.0334	CbGeAlD
Alprostadil—Testicular disorder—Doxorubicin—muscle cancer	0.00374	0.0258	CcSEcCtD
Alprostadil—SLCO2A1—renal system—muscle cancer	0.00373	0.0331	CbGeAlD
Alprostadil—SLCO3A1—cardiac atrium—muscle cancer	0.00337	0.0299	CbGeAlD
Alprostadil—SLCO2A1—cardiac atrium—muscle cancer	0.00334	0.0296	CbGeAlD
Alprostadil—ABCC5—cardiac atrium—muscle cancer	0.00305	0.0271	CbGeAlD
Alprostadil—SLCO3A1—tendon—muscle cancer	0.00294	0.0261	CbGeAlD
Alprostadil—SLCO2A1—tendon—muscle cancer	0.00291	0.0258	CbGeAlD
Alprostadil—PTGIR—head—muscle cancer	0.00285	0.0253	CbGeAlD
Alprostadil—Cerebral haemorrhage—Vincristine—muscle cancer	0.00279	0.0192	CcSEcCtD
Alprostadil—PTGIR—testis—muscle cancer	0.00276	0.0245	CbGeAlD
Alprostadil—SLCO3A1—vagina—muscle cancer	0.00273	0.0242	CbGeAlD
Alprostadil—SLCO2A1—vagina—muscle cancer	0.0027	0.024	CbGeAlD
Alprostadil—SLCO2B1—renal system—muscle cancer	0.00267	0.0237	CbGeAlD
Alprostadil—ABCC5—tendon—muscle cancer	0.00266	0.0236	CbGeAlD
Alprostadil—Fibrosis—Methotrexate—muscle cancer	0.00262	0.0181	CcSEcCtD
Alprostadil—ABCC5—bone marrow—muscle cancer	0.00258	0.0229	CbGeAlD
Alprostadil—Nodule—Methotrexate—muscle cancer	0.00255	0.0176	CcSEcCtD
Alprostadil—SLCO3A1—head—muscle cancer	0.00252	0.0224	CbGeAlD
Alprostadil—SLCO2A1—head—muscle cancer	0.00249	0.0221	CbGeAlD
Alprostadil—ABCC5—vagina—muscle cancer	0.00247	0.0219	CbGeAlD
Alprostadil—SLCO3A1—testis—muscle cancer	0.00243	0.0216	CbGeAlD
Alprostadil—Respiratory distress—Vincristine—muscle cancer	0.00243	0.0168	CcSEcCtD
Alprostadil—SLCO2A1—testis—muscle cancer	0.00241	0.0214	CbGeAlD
Alprostadil—Injection site haemorrhage—Doxorubicin—muscle cancer	0.00241	0.0166	CcSEcCtD
Alprostadil—ABCC4—renal system—muscle cancer	0.00236	0.021	CbGeAlD
Alprostadil—Diabetic—Methotrexate—muscle cancer	0.00224	0.0155	CcSEcCtD
Alprostadil—ABCC5—testis—muscle cancer	0.0022	0.0196	CbGeAlD
Alprostadil—Anuria—Methotrexate—muscle cancer	0.00214	0.0148	CcSEcCtD
Alprostadil—SLCO2B1—tendon—muscle cancer	0.00208	0.0185	CbGeAlD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—muscle cancer	0.00207	1	CrCbGaD
Alprostadil—Warmth—Doxorubicin—muscle cancer	0.00204	0.0141	CcSEcCtD
Alprostadil—Injection site inflammation—Doxorubicin—muscle cancer	0.00194	0.0134	CcSEcCtD
Alprostadil—Numbness—Vincristine—muscle cancer	0.00186	0.0128	CcSEcCtD
Alprostadil—Anuria—Doxorubicin—muscle cancer	0.00185	0.0128	CcSEcCtD
Alprostadil—ABCC4—tendon—muscle cancer	0.00184	0.0164	CbGeAlD
Alprostadil—ABCC4—bone marrow—muscle cancer	0.00179	0.0159	CbGeAlD
Alprostadil—SLCO2B1—head—muscle cancer	0.00179	0.0158	CbGeAlD
Alprostadil—Sensory loss—Vincristine—muscle cancer	0.00178	0.0123	CcSEcCtD
Alprostadil—Supraventricular extrasystoles—Doxorubicin—muscle cancer	0.00174	0.012	CcSEcCtD
Alprostadil—SLCO2B1—testis—muscle cancer	0.00172	0.0153	CbGeAlD
Alprostadil—Hypochromic anaemia—Doxorubicin—muscle cancer	0.00167	0.0115	CcSEcCtD
Alprostadil—ABCC4—head—muscle cancer	0.00158	0.014	CbGeAlD
Alprostadil—Tooth abscess—Doxorubicin—muscle cancer	0.00155	0.0107	CcSEcCtD
Alprostadil—ABCC4—testis—muscle cancer	0.00153	0.0136	CbGeAlD
Alprostadil—Prostatic disorder—Doxorubicin—muscle cancer	0.00152	0.0105	CcSEcCtD
Alprostadil—Numbness—Etoposide—muscle cancer	0.00151	0.0104	CcSEcCtD
Alprostadil—Sepsis—Dactinomycin—muscle cancer	0.0015	0.0103	CcSEcCtD
Alprostadil—Apnoea—Etoposide—muscle cancer	0.00147	0.0102	CcSEcCtD
Alprostadil—Sensory loss—Etoposide—muscle cancer	0.00144	0.00995	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Doxorubicin—muscle cancer	0.00132	0.00912	CcSEcCtD
Alprostadil—Pneumothorax—Doxorubicin—muscle cancer	0.0013	0.00899	CcSEcCtD
Alprostadil—Multiple fractures—Methotrexate—muscle cancer	0.00129	0.00888	CcSEcCtD
Alprostadil—Fracture—Methotrexate—muscle cancer	0.00129	0.00888	CcSEcCtD
Alprostadil—Lethargy—Dactinomycin—muscle cancer	0.00128	0.00882	CcSEcCtD
Alprostadil—Local reaction—Doxorubicin—muscle cancer	0.00117	0.00808	CcSEcCtD
Alprostadil—Body temperature decreased—Doxorubicin—muscle cancer	0.00116	0.00798	CcSEcCtD
Alprostadil—Hypothermia—Doxorubicin—muscle cancer	0.00116	0.00798	CcSEcCtD
Alprostadil—Pain in extremity—Vincristine—muscle cancer	0.00112	0.00772	CcSEcCtD
Alprostadil—Sepsis—Etoposide—muscle cancer	0.00108	0.00748	CcSEcCtD
Alprostadil—Burning sensation—Methotrexate—muscle cancer	0.00108	0.00743	CcSEcCtD
Alprostadil—Pelvic pain—Doxorubicin—muscle cancer	0.00107	0.00735	CcSEcCtD
Alprostadil—Cardiac arrest—Vincristine—muscle cancer	0.00106	0.00735	CcSEcCtD
Alprostadil—Serum creatinine increased—Doxorubicin—muscle cancer	0.00105	0.00727	CcSEcCtD
Alprostadil—Swelling—Etoposide—muscle cancer	0.00103	0.00709	CcSEcCtD
Alprostadil—Cardiac failure congestive—Etoposide—muscle cancer	0.001	0.0069	CcSEcCtD
Alprostadil—Fungal infection—Methotrexate—muscle cancer	0.000969	0.00669	CcSEcCtD
Alprostadil—Redness—Doxorubicin—muscle cancer	0.00096	0.00662	CcSEcCtD
Alprostadil—Burning sensation—Doxorubicin—muscle cancer	0.000933	0.00644	CcSEcCtD
Alprostadil—Apnoea—Methotrexate—muscle cancer	0.000883	0.00609	CcSEcCtD
Alprostadil—Cardiac arrest—Etoposide—muscle cancer	0.000862	0.00595	CcSEcCtD
Alprostadil—Pharyngitis—Dactinomycin—muscle cancer	0.00086	0.00594	CcSEcCtD
Alprostadil—Acute coronary syndrome—Vincristine—muscle cancer	0.000851	0.00587	CcSEcCtD
Alprostadil—Myocardial infarction—Vincristine—muscle cancer	0.000846	0.00584	CcSEcCtD
Alprostadil—Fungal infection—Doxorubicin—muscle cancer	0.000839	0.00579	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.000834	0.00576	CcSEcCtD
Alprostadil—Feeling hot—Doxorubicin—muscle cancer	0.000826	0.0057	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.000823	0.00568	CcSEcCtD
Alprostadil—Flushing—Dactinomycin—muscle cancer	0.000805	0.00555	CcSEcCtD
Alprostadil—Injection site pain—Doxorubicin—muscle cancer	0.000794	0.00548	CcSEcCtD
Alprostadil—Hypoaesthesia—Vincristine—muscle cancer	0.000771	0.00532	CcSEcCtD
Alprostadil—Sweating increased—Etoposide—muscle cancer	0.000764	0.00527	CcSEcCtD
Alprostadil—Urethral disorder—Vincristine—muscle cancer	0.000759	0.00524	CcSEcCtD
Alprostadil—Erythema—Dactinomycin—muscle cancer	0.000755	0.00521	CcSEcCtD
Alprostadil—Vasodilation procedure—Doxorubicin—muscle cancer	0.000738	0.00509	CcSEcCtD
Alprostadil—Vasodilation—Doxorubicin—muscle cancer	0.000738	0.00509	CcSEcCtD
Alprostadil—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000713	0.00492	CcSEcCtD
Alprostadil—Anaemia—Dactinomycin—muscle cancer	0.000697	0.00481	CcSEcCtD
Alprostadil—Acute coronary syndrome—Etoposide—muscle cancer	0.000689	0.00475	CcSEcCtD
Alprostadil—Renal failure—Etoposide—muscle cancer	0.000687	0.00474	CcSEcCtD
Alprostadil—Myocardial infarction—Etoposide—muscle cancer	0.000685	0.00473	CcSEcCtD
Alprostadil—Ecchymosis—Methotrexate—muscle cancer	0.000677	0.00467	CcSEcCtD
Alprostadil—Back pain—Vincristine—muscle cancer	0.000652	0.0045	CcSEcCtD
Alprostadil—Sepsis—Methotrexate—muscle cancer	0.000649	0.00448	CcSEcCtD
Alprostadil—Injection site reaction—Doxorubicin—muscle cancer	0.000644	0.00444	CcSEcCtD
Alprostadil—Hyperkalaemia—Doxorubicin—muscle cancer	0.000637	0.00439	CcSEcCtD
Alprostadil—Discomfort—Dactinomycin—muscle cancer	0.000635	0.00438	CcSEcCtD
Alprostadil—Influenza like illness—Doxorubicin—muscle cancer	0.000629	0.00434	CcSEcCtD
Alprostadil—Diabetes mellitus—Methotrexate—muscle cancer	0.000625	0.00431	CcSEcCtD
Alprostadil—Hypoaesthesia—Etoposide—muscle cancer	0.000624	0.00431	CcSEcCtD
Alprostadil—Anaemia—Vincristine—muscle cancer	0.000623	0.0043	CcSEcCtD
Alprostadil—Oedema—Dactinomycin—muscle cancer	0.000616	0.00425	CcSEcCtD
Alprostadil—Urethral disorder—Etoposide—muscle cancer	0.000615	0.00424	CcSEcCtD
Alprostadil—Infection—Dactinomycin—muscle cancer	0.000612	0.00422	CcSEcCtD
Alprostadil—Thrombocytopenia—Dactinomycin—muscle cancer	0.000603	0.00416	CcSEcCtD
Alprostadil—Cramps of lower extremities—Doxorubicin—muscle cancer	0.000595	0.00411	CcSEcCtD
Alprostadil—Ecchymosis—Doxorubicin—muscle cancer	0.000586	0.00404	CcSEcCtD
Alprostadil—Convulsion—Vincristine—muscle cancer	0.000584	0.00403	CcSEcCtD
Alprostadil—Flushing—Etoposide—muscle cancer	0.000582	0.00402	CcSEcCtD
Alprostadil—Hypertension—Vincristine—muscle cancer	0.000582	0.00402	CcSEcCtD
Alprostadil—Abnormal vision—Doxorubicin—muscle cancer	0.000565	0.0039	CcSEcCtD
Alprostadil—Sepsis—Doxorubicin—muscle cancer	0.000562	0.00388	CcSEcCtD
Alprostadil—Lethargy—Methotrexate—muscle cancer	0.000554	0.00382	CcSEcCtD
Alprostadil—Oedema—Vincristine—muscle cancer	0.00055	0.0038	CcSEcCtD
Alprostadil—Infection—Vincristine—muscle cancer	0.000547	0.00377	CcSEcCtD
Alprostadil—Diabetes mellitus—Doxorubicin—muscle cancer	0.000541	0.00373	CcSEcCtD
Alprostadil—Thrombocytopenia—Vincristine—muscle cancer	0.000539	0.00372	CcSEcCtD
Alprostadil—Hyperhidrosis—Vincristine—muscle cancer	0.000532	0.00367	CcSEcCtD
Alprostadil—Back pain—Etoposide—muscle cancer	0.000528	0.00365	CcSEcCtD
Alprostadil—Pain—Dactinomycin—muscle cancer	0.000527	0.00363	CcSEcCtD
Alprostadil—Muscle spasms—Etoposide—muscle cancer	0.000525	0.00362	CcSEcCtD
Alprostadil—Cardiac failure congestive—Doxorubicin—muscle cancer	0.000519	0.00358	CcSEcCtD
Alprostadil—Hypotension—Vincristine—muscle cancer	0.000514	0.00355	CcSEcCtD
Alprostadil—Feeling abnormal—Dactinomycin—muscle cancer	0.000508	0.0035	CcSEcCtD
Alprostadil—Anaemia—Etoposide—muscle cancer	0.000505	0.00348	CcSEcCtD
Alprostadil—Abdominal pain—Dactinomycin—muscle cancer	0.000487	0.00336	CcSEcCtD
Alprostadil—Body temperature increased—Dactinomycin—muscle cancer	0.000487	0.00336	CcSEcCtD
Alprostadil—Hypoglycaemia—Doxorubicin—muscle cancer	0.000482	0.00333	CcSEcCtD
Alprostadil—Loss of consciousness—Etoposide—muscle cancer	0.00048	0.00331	CcSEcCtD
Alprostadil—Lethargy—Doxorubicin—muscle cancer	0.00048	0.00331	CcSEcCtD
Alprostadil—Cough—Etoposide—muscle cancer	0.000477	0.00329	CcSEcCtD
Alprostadil—Convulsion—Etoposide—muscle cancer	0.000473	0.00327	CcSEcCtD
Alprostadil—Hypertension—Etoposide—muscle cancer	0.000472	0.00325	CcSEcCtD
Alprostadil—Pain—Vincristine—muscle cancer	0.000471	0.00325	CcSEcCtD
Alprostadil—Pain in extremity—Doxorubicin—muscle cancer	0.00047	0.00325	CcSEcCtD
Alprostadil—Discomfort—Etoposide—muscle cancer	0.000459	0.00317	CcSEcCtD
Alprostadil—Cardiac arrest—Doxorubicin—muscle cancer	0.000447	0.00309	CcSEcCtD
Alprostadil—Infection—Etoposide—muscle cancer	0.000443	0.00306	CcSEcCtD
Alprostadil—Asthenia—Dactinomycin—muscle cancer	0.000442	0.00305	CcSEcCtD
Alprostadil—Blood creatinine increased—Doxorubicin—muscle cancer	0.000441	0.00304	CcSEcCtD
Alprostadil—Thrombocytopenia—Etoposide—muscle cancer	0.000436	0.00301	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000436	0.00301	CcSEcCtD
Alprostadil—Tachycardia—Etoposide—muscle cancer	0.000435	0.003	CcSEcCtD
Alprostadil—Body temperature increased—Vincristine—muscle cancer	0.000435	0.003	CcSEcCtD
Alprostadil—Abdominal pain—Vincristine—muscle cancer	0.000435	0.003	CcSEcCtD
Alprostadil—Skin disorder—Etoposide—muscle cancer	0.000433	0.00299	CcSEcCtD
Alprostadil—Hyperhidrosis—Etoposide—muscle cancer	0.000431	0.00297	CcSEcCtD
Alprostadil—Hypokalaemia—Doxorubicin—muscle cancer	0.000428	0.00295	CcSEcCtD
Alprostadil—Diarrhoea—Dactinomycin—muscle cancer	0.000421	0.00291	CcSEcCtD
Alprostadil—Hypotension—Etoposide—muscle cancer	0.000417	0.00287	CcSEcCtD
Alprostadil—Renal failure—Methotrexate—muscle cancer	0.000412	0.00284	CcSEcCtD
Alprostadil—Influenza—Doxorubicin—muscle cancer	0.000407	0.00281	CcSEcCtD
Alprostadil—Haematuria—Methotrexate—muscle cancer	0.000399	0.00275	CcSEcCtD
Alprostadil—Asthenia—Vincristine—muscle cancer	0.000395	0.00272	CcSEcCtD
Alprostadil—Bronchitis—Doxorubicin—muscle cancer	0.000391	0.0027	CcSEcCtD
Alprostadil—Rash—Dactinomycin—muscle cancer	0.000388	0.00268	CcSEcCtD
Alprostadil—Pain—Etoposide—muscle cancer	0.000381	0.00263	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000378	0.00261	CcSEcCtD
Alprostadil—Haemoglobin—Methotrexate—muscle cancer	0.000378	0.00261	CcSEcCtD
Alprostadil—Diarrhoea—Vincristine—muscle cancer	0.000376	0.0026	CcSEcCtD
Alprostadil—Haemorrhage—Methotrexate—muscle cancer	0.000376	0.00259	CcSEcCtD
Alprostadil—Pollakiuria—Doxorubicin—muscle cancer	0.000376	0.00259	CcSEcCtD
Alprostadil—Pharyngitis—Methotrexate—muscle cancer	0.000373	0.00257	CcSEcCtD
Alprostadil—Urethral disorder—Methotrexate—muscle cancer	0.000368	0.00254	CcSEcCtD
Alprostadil—Feeling abnormal—Etoposide—muscle cancer	0.000367	0.00253	CcSEcCtD
Alprostadil—Hyperglycaemia—Doxorubicin—muscle cancer	0.000367	0.00253	CcSEcCtD
Alprostadil—Nausea—Dactinomycin—muscle cancer	0.000366	0.00252	CcSEcCtD
Alprostadil—Dizziness—Vincristine—muscle cancer	0.000364	0.00251	CcSEcCtD
Alprostadil—Visual impairment—Methotrexate—muscle cancer	0.000362	0.0025	CcSEcCtD
Alprostadil—Renal failure—Doxorubicin—muscle cancer	0.000356	0.00246	CcSEcCtD
Alprostadil—Abdominal pain—Etoposide—muscle cancer	0.000352	0.00243	CcSEcCtD
Alprostadil—Body temperature increased—Etoposide—muscle cancer	0.000352	0.00243	CcSEcCtD
Alprostadil—Urinary tract infection—Doxorubicin—muscle cancer	0.000352	0.00243	CcSEcCtD
Alprostadil—Rash—Vincristine—muscle cancer	0.000347	0.00239	CcSEcCtD
Alprostadil—Dermatitis—Vincristine—muscle cancer	0.000347	0.00239	CcSEcCtD
Alprostadil—Haematuria—Doxorubicin—muscle cancer	0.000346	0.00238	CcSEcCtD
Alprostadil—Headache—Vincristine—muscle cancer	0.000345	0.00238	CcSEcCtD
Alprostadil—Sinusitis—Doxorubicin—muscle cancer	0.00034	0.00235	CcSEcCtD
Alprostadil—Bradycardia—Doxorubicin—muscle cancer	0.000331	0.00229	CcSEcCtD
Alprostadil—Erythema—Methotrexate—muscle cancer	0.000327	0.00226	CcSEcCtD
Alprostadil—Haemoglobin—Doxorubicin—muscle cancer	0.000327	0.00226	CcSEcCtD
Alprostadil—Nausea—Vincristine—muscle cancer	0.000327	0.00226	CcSEcCtD
Alprostadil—Rhinitis—Doxorubicin—muscle cancer	0.000326	0.00225	CcSEcCtD
Alprostadil—Haemorrhage—Doxorubicin—muscle cancer	0.000325	0.00225	CcSEcCtD
Alprostadil—Hypoaesthesia—Doxorubicin—muscle cancer	0.000324	0.00223	CcSEcCtD
Alprostadil—Pharyngitis—Doxorubicin—muscle cancer	0.000323	0.00223	CcSEcCtD
Alprostadil—Asthenia—Etoposide—muscle cancer	0.00032	0.00221	CcSEcCtD
Alprostadil—Urethral disorder—Doxorubicin—muscle cancer	0.000319	0.0022	CcSEcCtD
Alprostadil—Back pain—Methotrexate—muscle cancer	0.000316	0.00218	CcSEcCtD
Alprostadil—Pruritus—Etoposide—muscle cancer	0.000315	0.00218	CcSEcCtD
Alprostadil—Visual impairment—Doxorubicin—muscle cancer	0.000314	0.00216	CcSEcCtD
Alprostadil—Diarrhoea—Etoposide—muscle cancer	0.000305	0.0021	CcSEcCtD
Alprostadil—Anaemia—Methotrexate—muscle cancer	0.000302	0.00209	CcSEcCtD
Alprostadil—Flushing—Doxorubicin—muscle cancer	0.000302	0.00208	CcSEcCtD
Alprostadil—Dizziness—Etoposide—muscle cancer	0.000295	0.00203	CcSEcCtD
Alprostadil—Cough—Methotrexate—muscle cancer	0.000285	0.00197	CcSEcCtD
Alprostadil—Convulsion—Methotrexate—muscle cancer	0.000283	0.00196	CcSEcCtD
Alprostadil—Erythema—Doxorubicin—muscle cancer	0.000283	0.00195	CcSEcCtD
Alprostadil—Rash—Etoposide—muscle cancer	0.000281	0.00194	CcSEcCtD
Alprostadil—Dermatitis—Etoposide—muscle cancer	0.000281	0.00194	CcSEcCtD
Alprostadil—Headache—Etoposide—muscle cancer	0.000279	0.00193	CcSEcCtD
Alprostadil—Discomfort—Methotrexate—muscle cancer	0.000275	0.0019	CcSEcCtD
Alprostadil—Nervousness—Doxorubicin—muscle cancer	0.000275	0.0019	CcSEcCtD
Alprostadil—Back pain—Doxorubicin—muscle cancer	0.000274	0.00189	CcSEcCtD
Alprostadil—Muscle spasms—Doxorubicin—muscle cancer	0.000272	0.00188	CcSEcCtD
Alprostadil—Infection—Methotrexate—muscle cancer	0.000265	0.00183	CcSEcCtD
Alprostadil—Nausea—Etoposide—muscle cancer	0.000265	0.00183	CcSEcCtD
Alprostadil—Anaemia—Doxorubicin—muscle cancer	0.000262	0.00181	CcSEcCtD
Alprostadil—Thrombocytopenia—Methotrexate—muscle cancer	0.000261	0.0018	CcSEcCtD
Alprostadil—Skin disorder—Methotrexate—muscle cancer	0.000259	0.00179	CcSEcCtD
Alprostadil—Hyperhidrosis—Methotrexate—muscle cancer	0.000258	0.00178	CcSEcCtD
Alprostadil—Syncope—Doxorubicin—muscle cancer	0.000254	0.00175	CcSEcCtD
Alprostadil—Hypotension—Methotrexate—muscle cancer	0.000249	0.00172	CcSEcCtD
Alprostadil—Loss of consciousness—Doxorubicin—muscle cancer	0.000249	0.00172	CcSEcCtD
Alprostadil—Cough—Doxorubicin—muscle cancer	0.000247	0.00171	CcSEcCtD
Alprostadil—Convulsion—Doxorubicin—muscle cancer	0.000245	0.00169	CcSEcCtD
Alprostadil—Hypertension—Doxorubicin—muscle cancer	0.000245	0.00169	CcSEcCtD
Alprostadil—Discomfort—Doxorubicin—muscle cancer	0.000238	0.00164	CcSEcCtD
Alprostadil—Dry mouth—Doxorubicin—muscle cancer	0.000236	0.00163	CcSEcCtD
Alprostadil—Dyspepsia—Methotrexate—muscle cancer	0.000235	0.00162	CcSEcCtD
Alprostadil—Oedema—Doxorubicin—muscle cancer	0.000231	0.0016	CcSEcCtD
Alprostadil—Infection—Doxorubicin—muscle cancer	0.00023	0.00158	CcSEcCtD
Alprostadil—Pain—Methotrexate—muscle cancer	0.000228	0.00158	CcSEcCtD
Alprostadil—Shock—Doxorubicin—muscle cancer	0.000227	0.00157	CcSEcCtD
Alprostadil—Thrombocytopenia—Doxorubicin—muscle cancer	0.000226	0.00156	CcSEcCtD
Alprostadil—Tachycardia—Doxorubicin—muscle cancer	0.000226	0.00156	CcSEcCtD
Alprostadil—Skin disorder—Doxorubicin—muscle cancer	0.000225	0.00155	CcSEcCtD
Alprostadil—Hyperhidrosis—Doxorubicin—muscle cancer	0.000224	0.00154	CcSEcCtD
Alprostadil—Feeling abnormal—Methotrexate—muscle cancer	0.00022	0.00152	CcSEcCtD
Alprostadil—Hypotension—Doxorubicin—muscle cancer	0.000216	0.00149	CcSEcCtD
Alprostadil—Abdominal pain—Methotrexate—muscle cancer	0.000211	0.00146	CcSEcCtD
Alprostadil—Body temperature increased—Methotrexate—muscle cancer	0.000211	0.00146	CcSEcCtD
Alprostadil—Dyspepsia—Doxorubicin—muscle cancer	0.000204	0.0014	CcSEcCtD
Alprostadil—Pain—Doxorubicin—muscle cancer	0.000198	0.00136	CcSEcCtD
Alprostadil—Asthenia—Methotrexate—muscle cancer	0.000192	0.00132	CcSEcCtD
Alprostadil—Feeling abnormal—Doxorubicin—muscle cancer	0.000191	0.00131	CcSEcCtD
Alprostadil—Pruritus—Methotrexate—muscle cancer	0.000189	0.0013	CcSEcCtD
Alprostadil—Body temperature increased—Doxorubicin—muscle cancer	0.000183	0.00126	CcSEcCtD
Alprostadil—Abdominal pain—Doxorubicin—muscle cancer	0.000183	0.00126	CcSEcCtD
Alprostadil—Diarrhoea—Methotrexate—muscle cancer	0.000183	0.00126	CcSEcCtD
Alprostadil—Dizziness—Methotrexate—muscle cancer	0.000177	0.00122	CcSEcCtD
Alprostadil—Rash—Methotrexate—muscle cancer	0.000168	0.00116	CcSEcCtD
Alprostadil—Dermatitis—Methotrexate—muscle cancer	0.000168	0.00116	CcSEcCtD
Alprostadil—Headache—Methotrexate—muscle cancer	0.000167	0.00115	CcSEcCtD
Alprostadil—Asthenia—Doxorubicin—muscle cancer	0.000166	0.00114	CcSEcCtD
Alprostadil—Pruritus—Doxorubicin—muscle cancer	0.000164	0.00113	CcSEcCtD
Alprostadil—Nausea—Methotrexate—muscle cancer	0.000159	0.00109	CcSEcCtD
Alprostadil—Diarrhoea—Doxorubicin—muscle cancer	0.000158	0.00109	CcSEcCtD
Alprostadil—Dizziness—Doxorubicin—muscle cancer	0.000153	0.00105	CcSEcCtD
Alprostadil—Rash—Doxorubicin—muscle cancer	0.000146	0.00101	CcSEcCtD
Alprostadil—Dermatitis—Doxorubicin—muscle cancer	0.000146	0.001	CcSEcCtD
Alprostadil—Headache—Doxorubicin—muscle cancer	0.000145	0.000999	CcSEcCtD
Alprostadil—Nausea—Doxorubicin—muscle cancer	0.000137	0.000948	CcSEcCtD
